Yourgene Health PLC Issue of share options and total voting rights (0334I)
12 April 2022 - 04:00PM
UK Regulatory
TIDMYGEN
RNS Number : 0334I
Yourgene Health PLC
12 April 2022
Yourgene Health plc
("Yourgene" or the "Company")
Issue of share options and total voting rights
Manchester, UK - 12 April 2022: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces the issuance
of an aggregate 1,130,000 share options to 20 mostly overseas
staff, for whom the Company's UK Share Incentive Plan is not
applicable. These new options are largely a substitution for
920,000 options which have lapsed in recent months due to the
departures of three leavers in the UK.
The options are exercisable in three tranches over three
financial years and are subject to certain performance conditions
in line with the Company's share option scheme rules and previously
issued share options. The exercise price of these options is 10
pence. The total number of share options now in issue is
59,828,471, representing c . 8.2% of the issued share capital or
c.7.6% of the enlarged share capital, assuming no other issuance
and that all of the currently issued options are exercised.
Total Voting Rights
For the purpose of the Disclosure and Transparency Rules, the
current issued share capital of the Company comprises 727,100,243
ordinary shares of 0.1p each. The Company does not hold any
ordinary shares in treasury. The above figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company, under the Disclosure
and Transparency Rules.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this
announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / Mob: 07584 391
303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKFLFFLZLFBBX
(END) Dow Jones Newswires
April 12, 2022 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Mar 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024